SCHEMBL6099799

SCHEMBL6099799

CCc1c(Cn2ccnc2-c2cccc(F)c2)nn2c(OC)cc(C)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.35
▸ MAPT P10636 8/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CSNK1D P48730 1/20 0.33
▸ CRHR1 P34998 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ BRD4 O60885 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ THRB P10828 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ MAT2A P31153 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15009373 0.89 PDE4B (0.38) MAPTALDH1A1KDM4ECRHR1MEN1
SCHEMBL6101186 0.85 GRM4 (0.34) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL6101905 0.75 KDR (0.36) KDRMAPTALDH1A1KDM4ENPSR1
SCHEMBL4773275 0.72 KDR (0.35) KDRMAPTALDH1A1KDM4ENPSR1
SCHEMBL5886351 0.72 ALDH1A1 (0.39) KDRMAPTALDH1A1KDM4ENPSR1
SCHEMBL4162740 0.71 ALDH1A1 (0.41) KDRMAPTALDH1A1KDM4ENPSR1
SCHEMBL6100424 0.69 ALDH1A1 (0.37) KDRMAPTALDH1A1KDM4ENPSR1
SCHEMBL10392077 0.69 ALDH1A1 (0.49) KDRMAPTALDH1A1KDM4ENPSR1
SCHEMBL5886317 0.69 BRD4 (0.40) KDRMAPTALDH1A1KDM4ENPSR1
SCHEMBL5886305 0.68 ALDH1A1 (0.39) KDRMAPTALDH1A1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130150351-A1 METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-06-13 — — US disclosed
US-20060014746-A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands NEUROGEN CORPORATION 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014746-A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands GABRA5, GABRA2, GABBR1 KDR 467/4885MAPT 2174/4885ALDH1A1 797/4885
US-20130150351-A1 METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY GABBR2, GABBR1, GABRR3 KDR 1303/4885MAPT 907/4885ALDH1A1 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback